Payment overview · 2025
General Payments
$843.09
27 reported records · 13 companies
Healthcare provider profile · identity verified
Ronald Anthony Berna, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOORESTOWN, NJ · NPI 1952345845
Verified facts
What the public records show
CMS Open Payments records show Ronald Anthony Berna, MD received $843.09 in general payments during 2025 across 27 reported records.
Janssen Biotech, Inc. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $168.19 | 19.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $144.09 | 17.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $119.72 | 14.2% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $102.35 | 12.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $87.81 | 10.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $50.88 | 6.0% | 3 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $50.54 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.40 | 4.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.43 | 2.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.55 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.69 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.92 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $843.09 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $218.73 | 3 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $119.72 | 1 | 2025 |
Source payment records
|
|||||
| Absorica LD Normalized: absorica ld |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $102.35 | 1 | 2025 |
Source payment records
|
|||||
| ILUMYA Normalized: ilumya |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $102.35 | 1 | 2025 |
Source payment records
|
|||||
| Winlevi Normalized: winlevi |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $102.35 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.02 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.02 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $57.00 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $50.88 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.08 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
138 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1010 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 823 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 109 |
| Furosemide | Furosemide | 573 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 469 | 92 |
| Sertraline Hcl | Sertraline Hcl | 383 | 68 |
| Losartan Potassium | Losartan Potassium | 355 | 78 |
| Eliquis | Apixaban | 341 | 52 |
| Lisinopril | Lisinopril | 338 | 58 |
| Famotidine | Famotidine | 286 | 55 |
| Gabapentin | Gabapentin | 284 | 62 |
| Donepezil Hcl | Donepezil Hcl | 264 | 36 |
| Omeprazole | Omeprazole | 229 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 225 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 48 |
| Memantine Hcl | Memantine Hcl | 217 | 29 |
| Potassium Chloride | Potassium Chloride | 210 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 36 |
| Mirtazapine | Mirtazapine | 188 | 33 |
| Metformin Hcl | Metformin Hcl | 179 | 39 |
| Latanoprost | Latanoprost | 165 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 26 |
| Carvedilol | Carvedilol | 144 | 23 |
| Lorazepam | Lorazepam | 143 | 50 |
| Xarelto | Rivaroxaban | 138 | 16 |
| Trazodone Hcl | Trazodone Hcl | 134 | 34 |
| Atenolol | Atenolol | 133 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 45 |
| Buspirone Hcl | Buspirone Hcl | 123 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 24 |
| Ezetimibe | Ezetimibe | 120 | 28 |
| Simvastatin | Simvastatin | 114 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 19 |
| Alprazolam | Alprazolam | 104 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 103 | 13 |
| Divalproex Sodium | Divalproex Sodium | 101 | 14 |
| Allopurinol | Allopurinol | 99 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 69 |
| Cephalexin | Cephalexin | 93 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 14 |
| Tramadol Hcl | Tramadol Hcl | 86 | 20 |
| Prednisone | Prednisone | 85 | 49 |
| Glimepiride | Glimepiride | 79 | 19 |
| Finasteride | Finasteride | 76 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 16 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Amoxicillin | Amoxicillin | 73 | 59 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 12 |
| Januvia | Sitagliptin Phosphate | 65 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 27 |
| Jardiance | Empagliflozin | 63 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 40 |
| Brimonidine Tartrate | Brimonidine Tartrate | 60 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 57 | suppressed |
| Nystatin | Nystatin | 56 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 14 |
| Metformin Hcl Er | Metformin Hcl | 52 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | suppressed |
| Loperamide | Loperamide Hcl | 51 | 20 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 47 | 21 |
| Spironolactone | Spironolactone | 46 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Lidocaine | Lidocaine | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Mupirocin | Mupirocin | 42 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 12 |
| Cefuroxime | Cefuroxime Axetil | 40 | 32 |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 12 |
| Torsemide | Torsemide | 39 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Amantadine | Amantadine Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 28 |
| Clonazepam | Clonazepam | 35 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Ketoconazole | Ketoconazole | 33 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 12 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Nystop | Nystatin | 27 | 17 |
| Primidone | Primidone | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Repaglinide | Repaglinide | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 11 |
| Acetic Acid | Acetic Acid | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 19 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 12 |
| Diazepam | Diazepam | 22 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Xtampza Er | Oxycodone Myristate | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 16 | 14 |
| Naproxen | Naproxen | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | 11 |
| Ethacrynic Acid | Ethacrynic Acid | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Glatopa | Glatiramer Acetate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ivermectin | Ivermectin | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $843.09 · 27 records | Janssen Biotech, Inc. | AIRSUPRA, Absorica LD, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, FARXIGA, GARDASIL 9, GEMTESA, ILUMYA, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, SKYRIZI, TREMFYA, The Cologuard Plus Collection Kit, Wegovy, Winlevi, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error